What top creators are saying about Liquidia Corporation(LQDA)

The stock was noted as having fallen from around $70 to around $45. The speaker questioned whether the viewer had bought at the higher price but offered no broader investment view.

A caller asked about the company after a settlement, and Shkreli said, “They’re doing great.” The context and investment rationale were not explained, and the company identification may be uncertain.

The settlement is described as good and very bullish because it reduces fears that the drug could be pulled from the market. Restrictions may limit marketing and prescriptions, and the speaker does not predict where the stock will close.

The speaker viewed the settlement positively because it reduced the risk of the drug being removed from the market, while noting restrictions could limit commercial potential and that the stock reaction was weaker than expected.

The discussion, which only tentatively identifies Liquidia, described a stock case dependent on patent litigation, an appeal, and continued access to an ILD indication; the price scenario was speculative.

The stock was reported up 8% to 10% around $30 amid speculation that a settlement might be near, but the timing and outcome were uncertain.

The speaker was bullish, but the upside scenario depends on litigation, drug-label, and patent-appeal outcomes.

A sealed court stipulation with United Therapeutics was viewed as a potentially positive catalyst, but its terms and business implications are unknown. The reported price near $28 was not a target.

The speaker expressed confidence that Liquidia could be sold to Merck, presenting a speculative acquisition angle.

The speaker said they were betting on Liquidia and liked the opportunity, despite noting that its stock had been falling; no supporting thesis was provided.

The speaker said he remained invested and liked the opportunity, hoping the stock would come back strongly, but offered no detailed thesis or catalyst.

Liquidia reportedly rallied on a sealed stipulation in a legal matter with United Therapeutics. A settlement was only speculation, and the terms were unclear.

Involved in an ongoing legal dispute with United Therapeutics, with both sides expected to propose remedies in a court docket update; the dispute is a source of uncertainty.

The speaker said he was still in the position, but offered no clear investment thesis or detailed analysis.

The speakers saw a chance of a comeback but also called the stock overvalued and questioned when investors might recover their money. An appeal was discussed as uncertain and potentially not decisive.

Involved in ongoing patent litigation with United Therapeutics; proposed remedies and court updates could matter, but no outcome was predicted.

The speaker saw a good chance of a comeback and expected the company to win an appeal; physician familiarity with its drug was cited as support, while legal and competitive uncertainties remain.

Presented as a major past winner, rising from around $5 to roughly $72–$75; comments emphasize strong historical performance and volatility rather than a current buy recommendation.

The speaker said the stock could return to $100 if it wins its appeal, while noting that it had already been depressed and had fallen another 20%.

The stock was mentioned as failing to hold its rally, indicating short-term trading weakness, with no longer-term thesis provided.

A court ruling in favor of United Therapeutics could prevent Liquidia from selling its drug for ILD for 30 months, though its PAH business and potential appeal may preserve value. Speakers viewed it as a possible short-term rebound trade, while warning of further losses and significant uncertainty.

The speaker called Liquidia a huge buy despite a further 20% decline; the bullish outlook is conditional on winning its appeal.

United Therapeutics won a court case involving a patent tied to Liquidia's drug for ILD, creating significant legal and commercial risk. Earlier buy-the-dip ideas were speculative and the stock could continue declining.

Maintained as a historical bullish pick within the biotech strategy.

A director who had only ever purchased shares (34 previous trades) made his first-ever and largest sale for $19 million after a 200% price run-up, signaling the stock may be overvalued.

A powerful bearish signal as a long-time insider and consistent buyer made his first-ever and only-ever sale, which was a large, discretionary sale after the stock's recent strong performance.

Multiple insiders sold over $20 million in stock after a 60% price surge. The unprecedented size of the sales is a strong warning sign that insiders may believe the stock is now fully or over-valued.